Biogen Inc. (BIIB)
Nasdaq · Cambridge, Massachusetts, USA · Founded 1978 · CEO Christopher Viehbacher
Valuation summary
$136.04 fair value versus $247.13 in the market, a difference of -45.0%. Rated Sell.
| Fair value per share | $136.04 |
| Current share price | $247.13 |
| Upside / downside | -45.0% |
| Bear case | $82.68 |
| Bull case | $210.49 |
| Discount rate (WACC) | 9.9% |
| Terminal growth | 2.20% |
| Market capitalisation | $36B |
| EV / Sales | 4.2x |
About Biogen Inc.
Founded in 1978, among the earliest biotechnology companies. Christopher Viehbacher became CEO in 2022. Biogen built its franchise in multiple sclerosis, now facing generic competition, and has staked its future on Alzheimer's disease — Leqembi, developed with Eisai, is one of the first treatments shown to slow cognitive decline, though uptake has been slower than hoped.
Investment case
- Leqembi addresses an enormous unmet need with essentially no direct competition yet.
- Deep neuroscience expertise built over four decades.
- Trades at a low multiple with substantial cash generation from the legacy franchise.
Key risks
- The multiple sclerosis franchise is in structural decline as generics arrive.
- Leqembi still requires diagnostic confirmation and MRI monitoring, which has slowed adoption, although a subcutaneous autoinjector for starting therapy became available in the US in August 2026.
- A long record of pipeline disappointments has damaged credibility.
Recent developments
- 2026-10-28 · Q3 revenue of $2.8bn beats as the growth portfolio (Leqembi, Skyclarys, Zurzuvae) overtakes the legacy MS franchise source
- 2026-10-02 · Biogen reported 52-week Phase 2 data showing rapid and durable efficacy for litifilimab in cutaneous lupus erythematosus. source
- 2026-08-24 · Leqembi Iqlik subcutaneous autoinjector, approved in July for starting therapy, became available in the US for early Alzheimer's disease. source
- 2026-08-06 · Biogen completed its acquisition of RayThera, a private immunology small-molecule developer, in a deal agreed in June worth up to $1bn. source
Revenue by segment
| Multiple Sclerosis | 45% |
| Alzheimer's & Neurology | 22% |
| Biosimilars & Other | 33% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $10.5B | $2.0B |
| Year 2 | $10.8B | $2.0B |
| Year 3 | $11.0B | $2.0B |
| Year 4 | $11.3B | $2.1B |
| Year 5 | $11.5B | $2.1B |
What the street says
Cheap for identifiable reasons. The argument is whether Alzheimer's treatment scales before the base business erodes.
Comparable companies: ZTS · TEVA · BDX · TAK · A · GEHC · GSK · RMD
Open the interactive model, price chart and sensitivity grid →